Annji Pharmaceutical CoROCO:7754 +1.83%9 Pretax Margin % is -47,415.51% as of Dec. 2025. GuruFocus rates ROCO:7754 with a GF Score™ of 9/100. The stock has 6 warning signs investors should review. Among 938 Biotechnology companies, Annji Pharmaceutical Co ranks worse than 89.34% on this metric.
The historical rank and industry rank for Annji Pharmaceutical Co's Pretax Margin % or its related term are showing as below:
ROCO:7754'
s Pretax Margin % Range Over the Past 10 Years
Min: -14456.21 Med: -4738.73 Max: -202.59
Current: -4738.73
ROCO:7754's Pretax Margin % is ranked worse than 89.34% of 938
companies
in the Biotechnology industry
Industry Median: -89.895
vs ROCO:7754: -4738.73
Annji Pharmaceutical Co (ROCO:7754) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Annji Pharmaceutical Co Pretax Margin % Related Terms
Annji Pharmaceutical Co Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7754 vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, Annji Pharmaceutical Co's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Annji Pharmaceutical Co Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Annji Pharmaceutical Co's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Annji Pharmaceutical Co's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Annji Pharmaceutical Co (ROCO:7754) has a Pretax Margin % of -47,415.51% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Annji Pharmaceutical Co and its competitors. According to the industry distribution chart, Annji Pharmaceutical Co ranks #838 out of 938 companies in the Biotechnology industry, placing it in the top 89.3%.
Is Annji Pharmaceutical Co's Pretax Margin % too high?
Annji Pharmaceutical Co's current Pretax Margin % is -47,415.51%. Based on the distribution chart, Annji Pharmaceutical Co ranks #838 out of 938 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Annji Pharmaceutical Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Annji Pharmaceutical Co's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Annji Pharmaceutical Co ranks #838 out of 938 companies for Pretax Margin %. This places Annji Pharmaceutical Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Annji Pharmaceutical Co and its competitors. Annji Pharmaceutical Co's current Pretax Margin % is -47,415.51%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Annji Pharmaceutical Co stock overvalued right now?
Annji Pharmaceutical Co (ROCO:7754) has a current Pretax Margin % of -47,415.51%. The current Pretax Margin % is -47,415.51%. Annji Pharmaceutical Co's overall GF Score™ is 9/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Annji Pharmaceutical Co (ROCO:7754), the current Pretax Margin % is -47,415.51% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Annji Pharmaceutical Co Ltd is an R&D based, clinical-stage new drug company dedicated to the development of first-in-class small molecules focusing on indications with highly unmet needs in the therapeutic areas of neurology, dermatology, and inflammatory disorders, including rare diseases such as idiopathic pulmonary fibrosis and Kennedy's disease, or SBMA (Spinal and bulbar muscular atrophy). Its pipeline products include AJ201, AJ302 and AJ303.
9GF Score
Get the complete analysis for ROCO:7754
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7754 has been successfully added to your 